Navigation Links
EUCODIS Bioscience Launches Lipase Portfolio

VIENNA, Austria, September 21 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry, announced today that it has launched the first enzymes of its lipase portfolio. EUCODIS Bioscience currently offers 12 lipases that have been selected to cover a broad range of potential industrial applications.

Lipases are an enzyme family that is widely used across the chemical industry, including the pharmaceutical, cosmetics, textiles, and food and feed industries. EUCODIS Bioscience offers customers to supply lipases of interest up to the kilogram scale. The Company can also customize promising lipases to properties specified by the customer, using its proven in-vivo recombination technology.

"With the launch of our lipases portfolio we enter a market of USD 300 million," said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "In recent years our organization has accumulated a unique expertise in the development, customization, and manufacturing of industrial lipases. Our customers can select from our portfolio of currently 12 lipases which include both enzymes designed for well-established uses as well as those with exciting novel properties. Going forward we plan to expand our lipase platform and to leverage the industrial expertise we can offer in this area."

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visit

    Company contact EUCODIS Bioscience:
    Rudy Pandjaitan, PhD
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
2. EUCODIS Bioscience Signs Research Agreement With Genencor
3. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
4. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
5. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
7. American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience
8. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
9. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
10. Neurocrine Biosciences Secures Committed Equity Financing Facility
11. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
Breaking Biology Technology:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):